Cigna Group (CI) Could Be 17% Undervalued On Its $100 Million Evernorth AI Push
Cigna Group (CI) is potentially 17% undervalued despite its $100 million Evernorth AI initiative aimed at optimizing specialty pharmacy operations. The stock has seen a modest 2.82% 90-day share price return but an 8.10% decline over the past year, reflecting investor caution amid index removals and PBM regulatory pressures, even as its fair value is estimated at $340.92 against a current $281.98. The company is leveraging AI to capitalize on the growing $400B+ specialty pharmacy market, which is expected to drive long-term revenue and earnings growth.
Cigna Group stock underperforms Monday when compared to competitors
Cigna Group (CI) stock fell by 2.01% on Monday, closing at $281.98, despite an overall positive trading session for the broader stock market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains, but Cigna's decline ended its two-day winning streak. This performance indicates Cigna underperformed compared to its competitors and the general market trend.
UnitedHealth Bets on Profitability Over Growth: Will It Pay Off?
UnitedHealth Group (UNH) is shifting its focus from rapid enrollment growth to improving profitability due to a challenging operating environment. The company is repricing Medicare Advantage plans, exiting less profitable markets, and leveraging Optum's growth in value-based care and technology services. This strategic reset, showing early signs of success with improved first-quarter earnings and MCR, aims to restore earnings momentum and ensure long-term sustainability, an approach also being adopted by peers like Cigna and Elevance Health.
UnitedHealth Bets on Profitability Over Growth: Will It Pay Off?
UnitedHealth (UNH) is shifting its strategy from rapid enrollment growth to focus on profitability due to higher healthcare utilization and rising Medicare Advantage costs. The company is repricing plans, exiting less profitable markets, and leveraging Optum as a growth driver through value-based care and technology. Peers like Cigna (CI) and Elevance Health (ELV) are also prioritizing efficiency and quality growth in a challenging healthcare environment.
UnitedHealth Group highlights diversified health benefits and services portfolio as investors track long-term growth drivers
UnitedHealth Group Incorporated continues to emphasize its diversified portfolio of health benefits and services. The company's dual structure as both an insurer and a services provider, combining commercial, Medicare, and Medicaid plans with pharmacy benefits and data analytics, is a key feature. Investors are closely monitoring membership trends, medical cost management, and the company's role in the broader U.S. healthcare system.
RBC Capital Adjusts Helmerich & Payne Price Target to $44 From $40, Maintains Sector Perform Rating
RBC Capital has increased its price target for Helmerich & Payne (NYSE:HP) to $44 from $40, while reaffirming a Sector Perform rating for the company. This adjustment reflects an updated outlook from the financial institution on the oil and gas drilling firm's valuation.
Cigna Group outlines its role in US health coverage and benefits
Cigna Group is a major US health services company providing medical, pharmacy, and behavioral benefits, along with administrative services for employers and public programs. The company's business model focuses on designing and administering health benefit plans, improving health outcomes, and controlling cost growth. Its role in the US healthcare ecosystem is influenced by insurance regulation, medical cost inflation, and the growing demand for integrated health solutions.
Ambetter health plans from Centene Corp. - a key Obamacare product for US families
Ambetter health plans by Centene Corp. are a major product line on the Affordable Care Act (ACA) marketplaces, providing essential health benefits to millions of US families. The plans offer tiered options (bronze, silver, gold), digital tools, and focus on affordability for individuals and families without employer-sponsored coverage. Ambetter's presence across many states and its integration with ACA subsidies make it a significant player in the national health insurance landscape, affecting both consumers and Centene's financial performance.
THC - Tenet Healthcare Corp Latest SEC Filings
This article provides a detailed financial overview of Tenet Healthcare Corp (THC), including key financial metrics, stock performance data, and insider/institutional ownership percentages. It highlights the company's market capitalization, revenue, earnings per share, and various valuation ratios, alongside recent stock performance across different timeframes. The content appears to be a snapshot of financial data and not a news article.
Cigna Group highlights its health services strategy as a major U.S. insurer
Cigna Group is emphasizing its integrated health services and insurance model to compete with other major managed care companies in the U.S. The company focuses on providing medical, pharmacy, and behavioral benefits for employers and individuals. Its business model combines traditional health insurance with pharmacy benefit management and coordinated care offerings to manage costs and improve health outcomes.
Cigna (CI) Stock Just Lost Its Place In Key Russell Growth Indexes
Cigna (NYSE:CI) has been removed from major Russell equity indices, including the Russell 1000 Growth and Russell 3000 Growth. This technical event can influence portfolio rebalancing and fund flows for institutional and passive investors, rather than directly impacting Cigna's business operations. The company's stock is currently trading below analyst targets and estimated fair value, with recent positive momentum despite the index removal, though it carries a high level of debt.
Cigna (CI) Launches AI Pharmacy Program With $100 Million Behind It
Cigna's health services arm, Evernorth, has launched "Pharmacy Forward," an AI-powered specialty pharmacy program backed by a $100 million investment through 2028. This initiative aims to improve prescription fulfillment, medication adherence, and clinical interventions for over 1 million patients on specialty medications. The program signifies Cigna's strategic shift towards technology-driven health services and data-informed care coordination, allowing investors to gauge the company's capital allocation towards digital tools.
Cigna Group holds steady as investors await a fresh catalyst.
Cigna Group's stock remains steady as there's no new verified catalyst in the market, shifting investor focus to the company's established business model and the broader U.S. healthcare context. The health services company, operating through employer-sponsored coverage, government plans, and pharmacy benefits, relies on its scale, pricing discipline, and ability to manage costs. With no specific company-driven news, its valuation is currently influenced by the wider healthcare sector trends.
8 Health Care Stocks Whale Activity In Today’s Session
This article identifies significant options trading activity, often referred to as "whale activity," in eight healthcare stocks: DaVita (DVA), Intuitive Surgical (ISRG), Veeva Systems (VEEV), The Cigna Group (CI), Eli Lilly and Co (LLY), Moderna (MRNA), Centene Corp (CNC), and Molina Healthcare (MOH). The analysis details specific call and put options, their sentiment (bullish or bearish), expiration dates, strike prices, total trade prices, open interest, and volume to help traders understand potential market movements. This information is generated by Benzinga's automated content engine to highlight unusual options activity.
HUM - Humana Inc Latest SEC Filings
This article provides the latest SEC filing information and comprehensive financial data for Humana Inc. (HUM). It details various financial metrics such as market cap, income, sales, P/E ratios, dividend information, and performance indicators, alongside insider ownership and institutional transactions. The data reflects the company's financial health and stock performance as of July 2, 2024.
CVS Health Corp. highlights evolving role in U.S. healthcare. Investors weigh integrated care strategy
CVS Health Corp. is expanding its integrated healthcare model, combining pharmacy, insurance, and clinical services to achieve long-term stability in the evolving U.S. healthcare landscape. The company's diversified approach, spanning retail pharmacies, pharmacy benefit management, and health insurance, aims to create a comprehensive care ecosystem. Investors are evaluating how effectively this integrated structure can translate into resilient earnings and improved patient outcomes through coordinated care.
Abacus Global Management, Inc. Announces Resignation of Sean McNealy as A Director, Effective June 30, 2026
Abacus Global Management, Inc. announced that Sean McNealy resigned as a director, effective June 30, 2026, due to his planned retirement. Mr. McNealy will continue as an advisor during a transition period and will resign from all subsidiary director or officer roles by December 31, 2026. His resignation is not due to any disagreement with the company's management, board, operations, policies, or practices.
Cigna Brings AI to Specialty Pharmacy With Pharmacy Forward
Cigna's health services division, Evernorth, has launched Pharmacy Forward, an AI-powered specialty pharmacy initiative backed by a $100 million investment. This program aims to simplify prescription journeys, reduce processing times by half, and improve patient adherence for complex conditions. With projections to generate nearly $400 million in cumulative value by 2028, this initiative strengthens Evernorth's position in the growing specialty pharmacy market and contributes to Cigna's long-term growth strategy.
Cigna Group stock outperforms competitors on strong trading day
Cigna Group (CI) shares rose 3.86% to $287.77 on Thursday, outperforming competitors and marking its second consecutive day of gains. This occurred during a mixed trading session, with the S&P 500 Index remaining stable and the Dow Jones Industrial Average increasing by 1.14%.
The Price They Pay: The Mental Health Toll on Working Moms
This article highlights a session at MACo’s 2026 Summer Conference, hosted by Cigna Healthcare, titled "The Price They Pay: The Mental Health Toll on Working Moms." The session description, however, focuses on expanding and strengthening school meal programs in Maryland, discussing their positive impact on students, schools, and communities by reducing future healthcare and social costs. It encourages attendees to register for the conference to learn more about this and other initiatives.
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare
Pacira BioSciences (PCRX) announced that UnitedHealthcare will now provide separate reimbursement for its non-opioid pain medicine, Exparel, in outpatient settings. This decision is expected to improve patient access and support the use of non-opioid pain management after surgery, following similar policies from other major insurers and expanded Medicare coverage. Exparel is Pacira's primary growth driver, with ongoing initiatives to expand its indications and geographic reach.
Molina Healthcare focuses on managed care growth as investors watch US health coverage trends
Molina Healthcare, a US-based managed care company, specializes in providing health insurance services through government programs like Medicaid and Medicare. The company's growth and profitability are closely tied to enrollment levels, effective management of medical costs relative to fixed payments, and the ever-changing policy environment surrounding public health coverage. Investors closely monitor these factors, along with regulatory developments and industry performance, to assess Molina Healthcare's financial health and future prospects.
Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth Strategy
DarioHealth Corp. announced that a top national health insurer has expanded its partnership to include Dario's hypertension solution, following the success of its behavioral health offering. This expansion is expected to approximately triple Dario's revenue opportunity with this customer and validates its multi-condition strategy. It marks the third health plan customer to broaden its deployment beyond an initial condition, reinforcing Dario's ability to grow within its existing customer base by delivering integrated care across various chronic conditions.
New Cigna CEO’s patient-first focus to face Wall Street test
The new CEO of Cigna, Brian Evanko, is set to face scrutiny from Wall Street as he implements a patient-first focus. This strategic direction will be a key test for the company's leadership and its impact on the healthcare market. The article highlights Cigna's new leadership direction under Evanko and the challenges and expectations from the financial community.
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
Pacira BioSciences announced that UnitedHealthcare will now provide separate reimbursement for EXPAREL® (bupivacaine liposome injectable suspension) in outpatient settings, including hospital outpatient departments and ambulatory surgery centers. This decision expands access to non-opioid postsurgical pain management for approximately 40 million UnitedHealthcare members. With this, a total of about 150 million covered lives nationwide now have access to separate reimbursement for EXPAREL, reducing financial barriers to non-opioid pain management.
Cigna's Evernorth division announces $100M specialty drug AI program
Cigna's Evernorth division is launching a $100 million artificial intelligence program focused on specialty drugs. The initiative will initially be implemented at Accredo, Evernorth's subsidiary that handles expensive and complex medications, aiming to leverage AI for improved management and outcomes of specialty drug therapies. Evernorth is the healthcare services business arm of Cigna.
Evernorth Invests $100M for AI Specialty Pharmacy Program
Evernorth, The Cigna Group's health services division, has committed $100 million through 2028 to its new AI-powered "Pharmacy Forward" program. This initiative aims to enhance specialty pharmacy operations and patient care by leveraging AI in areas like care enablement, experience accelerators, Rx readiness, and a unified fulfillment network. The program is initially launching with Accredo Specialty Pharmacy and is expected to generate $400 million in value by late 2028.
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL
Pacira BioSciences announced that UnitedHealthcare will now provide separate reimbursement for EXPAREL (bupivacaine liposome injectable suspension) in outpatient settings, expanding access to non-opioid postsurgical pain management for approximately 40 million covered lives. This move, following similar policies from other major payers and the NOPAIN Act, aims to remove financial barriers and support clinician-led decisions for pain management. Pacira emphasizes its commitment to collaborating with healthcare stakeholders to advance non-opioid pain therapy access and value.
Cigna’s Evernorth Makes $100 Million AI Specialty Pharmacy Investment
Cigna's Evernorth health services business is investing $100 million through 2028 into a new AI-powered "Pharmacy Forward" program. This initiative aims to improve patient access and experience with specialty care, starting with Accredo Specialty Pharmacy. The investment focuses on leveraging AI, data, and analytics to offer personalized support, reduce prescription processing times, and enhance clinical care for patients with complex and chronic conditions.
Cigna’s Evernorth Makes $100 Million AI Specialty Pharmacy Investment
Cigna's Evernorth is investing $100 million by 2028 into "Pharmacy Forward," an AI-powered program aimed at revolutionizing specialty drug access and managing rising costs, particularly from anti-obesity medications. The initiative, starting with Accredo Specialty Pharmacy, will use AI, data, and clinical expertise to provide personalized patient support, streamline prescription processing, and ensure efficient, same-day/next-day ground shipping for over 90% of patients. This investment intends to empower care teams to focus more on clinical outcomes for patients with complex conditions by improving service responsiveness and reducing processing timelines.
Cigna’s Evernorth Makes $100 Million AI Specialty Pharmacy Investment
Cigna's Evernorth health services business is investing $100 million through 2028 into a new artificial intelligence-powered pharmacy program called "Pharmacy Forward." This initiative aims to enhance patient access and experience in specialty care, particularly for high-cost specialty drugs. The program will initially launch with Accredo Specialty Pharmacy, focusing on improving clinical care, reducing prescription processing times, and delivering more personalized support for patients with complex conditions.
SiTime Corporation completed the acquisition of Timing Business of Renesas Electronics America Inc.
SiTime Corporation successfully completed its acquisition of the Timing Business of Renesas Electronics America Inc. on July 1, 2026. This acquisition, valued at $3 billion, was financed through a combination of cash and stock consideration. The acquired business is expected to generate $300 million in revenue within 12 months post-close and is anticipated to be accretive to SiTime's non-GAAP earnings per share in its first year.
Cigna’s CEO vows to put patients first. Wall Street is watching
Cigna's new CEO, Brian Evanko, is prioritizing patient costs, a move closely observed by Wall Street. The article highlights other relevant stories in healthcare, including state-level 340B policy changes, a hospital-at-home program, and insurers' investments in AI.
UBS Adjusts SSR Mining Price Target to $39 From $40, Maintains Buy Rating
UBS has adjusted its price target for SSR Mining (SSRM) to $39 from $40, while reaffirming its "Buy" rating on the stock. This update comes shortly after a previous adjustment on June 30 when UBS lowered the target to $40 from $43, also with a maintained "Buy" rating. The article also notes recent additions of SSR Mining to various Russell growth and defensive benchmarks.
Cigna invests $100 million in new AI-powered specialty pharmacy program
Cigna's health services unit, Evernorth, has launched "Pharmacy Forward," a new AI-powered specialty pharmacy program supported by a $100 million investment. The program aims to streamline prescription processing, improve customer service by reducing clinician documentation time by up to 50%, and halve the time it takes for patients to receive medication after a prescription is received by Accredo. This initiative is expected to generate $400 million in value by the end of 2028.
New Cigna CEO’s Patient-First Focus to Face Wall Street Test (1)
Cigna's new CEO, Brian Evanko, plans to center the company's strategy on patients, a move that will require convincing consumers struggling with healthcare costs and reassuring Wall Street about profitability. The company previously announced phasing out rebate payments from drug companies in many of its prescription plans, a practice criticized by the Trump administration, with the goal of lowering patient costs. This strategy poses a challenging balancing act for Cigna, as it seeks to prioritize patient-first initiatives while maintaining financial health.
Pacira BioSciences' Exparel Now Separately Reimbursed by UnitedHealthcare Across Outpatient Settings
Pacira BioSciences' Exparel, a long-acting local anesthetic, will now receive separate reimbursement from UnitedHealthcare for use in outpatient settings. This development is significant as it improves access to EXPAREL for pain management, which is a non-opioid treatment. The separate reimbursement applies to infiltration, fascial plane block, and specific nerve blocks for postsurgical pain.
Cigna invests $100 million in new AI-powered specialty pharmacy program
Cigna's health services unit Evernorth has launched a new AI-powered specialty pharmacy program, "Pharmacy Forward," backed by a $100 million investment through 2028. This program aims to reduce prescription processing times, improve customer service, and cut clinician documentation time by up to 50% by integrating clinical data and streamlining prior authorization requests. The initiative is expected to generate approximately $400 million in value by the end of 2028.
Evernorth Launches Pharmacy Forward: A Simpler, Faster Specialty Pharmacy Experience for Patients Managing Complex Conditions
Evernorth, a division of The Cigna Group, has launched "Pharmacy Forward," an AI-powered program aimed at simplifying and accelerating the specialty pharmacy experience for patients with complex conditions. The program, backed by a $100 million investment, integrates AI across clinical care, prescription intake, administration, and medication fulfillment to improve adherence, streamline processes, and enhance patient support, initially through Accredo Specialty Pharmacy. It is expected to generate approximately $400 million in value by the end of 2028 and will be extended to other Evernorth pharmacies.
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
Pacira BioSciences announced that UnitedHealthcare will now provide separate reimbursement for EXPAREL® (bupivacaine liposome injectable suspension) across various outpatient settings. This development expands patient access to non-opioid postsurgical pain management for approximately 40 million UnitedHealthcare members. With this addition, EXPAREL now has separate reimbursement access for about 150 million covered lives nationwide, reducing financial barriers for patients seeking non-opioid pain solutions after surgery.
Raymond James Adjusts Price Target on Provident Financial Services to $27 From $25, Maintains Strong Buy Rating
Raymond James has increased its price target for Provident Financial Services (NYSE: PFS) from $25 to $27, while reiterating a "Strong Buy" rating on the stock. This adjustment reflects continued confidence in the financial services company. Provident Financial Services is the holding company for Provident Bank, providing various banking and financial services across New Jersey, Pennsylvania, and New York.
Evernorth unveils new AI-powered specialty pharmacy program, Pharmacy Forward
Evernorth has launched "Pharmacy Forward," an AI-powered specialty pharmacy program aimed at enhancing patient care for complex conditions. The program, which will initially serve Accredo Specialty Pharmacy customers, seeks to improve coordinated care, accelerate prescription processing, and free up clinical teams by reducing documentation. Evernorth plans to invest $100 million by 2028 and expects to generate $400 million in value through the program's efficiency and patient outcome improvements.
Evernorth Launches Pharmacy Forward: A Simpler, Faster Specialty Pharmacy Experience for Patients Managing Complex Conditions – Company Announcement - FT.com
Evernorth, the health services division of The Cigna Group, has launched "Pharmacy Forward," a new AI-powered program aimed at simplifying and expediting the specialty pharmacy experience for patients managing complex conditions. The program, backed by a $100 million investment through 2028, integrates AI across clinical care, prescription intake, administration, and medication fulfillment to improve adherence, reduce processing times, and deliver more personalized support. It is expected to generate approximately $400 million in value by the end of 2028 and will initially be rolled out through Accredo Specialty Pharmacy.
Citigroup Lifts Price Target on Generac to $300 From $263, Maintains Neutral Rating
Citigroup has raised its price target for Generac Holdings (GNRC) to $300 from $263, while maintaining a Neutral rating on the stock. This adjustment comes after other financial institutions like Barclays, Jefferies, UBS, and Stephens also updated their price targets for Generac in recent weeks.
Citigroup Adjusts Price Target on Leidos Holdings to $138 From $178, Maintains Buy Rating
Citigroup has lowered its price target for Leidos Holdings (LDOS) to $138 from $178. Despite the significant reduction in the price target, Citigroup has decided to maintain its "Buy" rating on the stock. This adjustment reflects a revised valuation perspective while still indicating a positive outlook for the company's shares.
RPM International Keeps Quarterly Dividend at $0.54 a Share, Payable July 31 to Holders of Record on July 14
RPM International Inc. has declared a regular quarterly cash dividend of $0.54 per share. This dividend is payable on July 31, 2026, to shareholders of record as of July 14, 2026. The announcement was made by MT Newswires.
US firms score roles on the $69bn CVS Health Aetna merger
McDermott Will & Schulte, a global law firm, advised CVS Health Corp. on its $69 billion acquisition of insurer Aetna Inc., a deal expected to significantly impact the US healthcare sector. The acquisition was one of the largest M&A transactions in 2017. Several partners from McDermott's offices in Washington, DC, Chicago, and Dallas were involved in this major deal.
The Evernorth Behavioral Health Program from Cigna Group - a quiet revenue engine in mental health care
Cigna Group's Evernorth Behavioral Health Program is highlighted as a strategic and quiet revenue driver within its health services arm. The program offers comprehensive in-person and virtual mental health support to millions of eligible members across the US, integrating with various third-party platforms and emphasizing coordinated care. Investors should recognize this program as a key contributor to Evernorth's growth and Cigna's long-term earnings profile, addressing the increasing demand for behavioral services.
Morgan Stanley Raises UnitedHealth Stock (UNH) Price Target Ahead of Q2 Earnings, Calls It ‘Top Pick’
Morgan Stanley analyst Erin Wright has increased her price target for UnitedHealth (UNH) to $468 from $453, maintaining it as a "Top Pick" ahead of its Q2 2026 earnings report on July 16. Wright anticipates UNH will set a positive tone for the MCO sector, citing favorable utilization trends and strong execution, particularly at Optum Health. She also highlights the company's significant investment in AI initiatives, projected to yield $1 billion in operating cost savings this year, and sees further valuation gains for UNH within the sector.
The Cigna Group (CI) Has a Health-Services Engine Bigger Than the Insurer Label
The Cigna Group (CI) should be evaluated beyond its traditional insurer label due to the significant growth and profitability of its Evernorth Health Services segment. Evernorth, encompassing pharmacy benefit management and care services, now contributes a substantial portion of Cigna's revenue and earnings, operating on a fee-based, capital-light model distinct from the medical-cost volatility of its insurance business. This shift provides the company with a more diversified earnings profile and strong cash generation, although medical costs, regulation, and client retention remain key areas for investors to monitor.
